approved$2.9B

Allogeneic cell therapy for inflammatory conditions, Ryoncil approved in Japan

phase 1 2$1.3B

Precision RNA therapeutics for genetic diseases, lead program VP-001 for retinitis pigmentosa

phase 3$1.1B

Copper-based radiopharmaceuticals for cancer imaging and therapy, SAR-bisPSMA lead program

phase 3$277M

WiSE wireless cardiac pacing system for heart failure

approved$443M

Global specialty pharma company with SCENESSE (afamelanotide) approved by FDA and EMA for erythropoietic protoporphyria, expanding into vitiligo and xeroderma pigmentosum.

phase 2$147M

Developing Xolatryp for STEMI reperfusion injury (Phase 2) and NYR-BI03 for brain injury (Phase 1 completed). Dual cardiovascular + neuroprotection pipeline.

phase 2$111M

Developing ISLA-101 (fenretinide) as a broad-spectrum antiviral, initially targeting dengue. Phase 2 human challenge study completed.

approved$91M

Nuclear medicine Technegas lung ventilation diagnostic

phase 1$93M

iNKT cell therapy platform for oncology

approved$47M

Predictive diagnostics company specialising in proteomics-based blood tests including PromarkerD for diabetic kidney disease

preclinical$40M

Developing EmtinB, a metal-attenuating peptide for neurodegenerative diseases including Alzheimer's and motor neurone disease.

approved$21M

MedTech company specialising in non-invasive MRI-based liver and heart iron assessment and clinical trial imaging services

approved$29M

Medical device company commercialising the SOZO bioimpedance spectroscopy platform, FDA-cleared for lymphedema detection and heart failure fluid monitoring, with 90%+ reimbursement coverage across 27 US states.

phase 1$10M

Deoxymabs (cell-penetrating antibodies) targeting intracellular DNA damage repair for cancer

approved$5M

Topical drug delivery technology, LENZETTO hormone therapy

phase 3$8M

Developing Presendin (repurposed drug) for idiopathic intracranial hypertension (IIH). Phase 3 trial terminated early; reassessing strategy.

phase 3$10M

Licensed RGTA (ReGeneraTing Agent) technology for wound healing and tissue repair. CACIPLIQ20 product in Phase 3 for scars.

approved$10M

Hyperimmune bovine colostrum antibodies for traveller's diarrhoea and NASH (Travelan, IMM-124E)

approved$674M

Vision-MR ablation system for cardiac catheter ablation under real-time MRI guidance

approved$244M

CelGro collagen scaffold for nerve and tendon repair; NeuraGen and TenGlide product lines

phase 3$234M

DMX-200 (atrasentan + irbesartan) in Phase 3 for focal segmental glomerulosclerosis (FSGS)

approved$207M

Specialty pharma focused on dermatology and women's health in the US market

approved$201M

Commercial-stage regenerative medicine company whose RECELL System delivers FDA-approved Spray-On Skin for burn wounds, full-thickness skin defects, and vitiligo repigmentation.

approved$161M

Point-of-care diagnostics company. FebriDx rapid test differentiates bacterial vs viral acute respiratory infections. Pediatric validation study recruiting.

approved$153M

Cxbladder — urine-based mRNA test for bladder cancer detection, monitoring and surveillance

phase 2$120M

Clinical-stage biopharma developing ATH434, an oral iron chaperone targeting pathological iron accumulation in neurodegenerative diseases including multiple system atrophy.

approved$116M

Mandibular advancement devices (MAD) for obstructive sleep apnea; sold in 28 countries

phase 2 3$109M

Clinical-stage biotech developing LAG-3-based immunotherapies for cancer and autoimmune disease; lead asset eftilagimod alpha is in Phase 2/3 for breast cancer and HNSCC.

phase 1 2$80M

FAK inhibitor AMP945 for pancreatic and ovarian cancer

preclinical$46M

Cancer diagnostics company developing EXO-NET exosome capture technology and SubB2M biomarker platform for early cancer detection.

preclinical$31M

Developing a simple blood test for early breast cancer detection using calcium-binding biomarkers.

approved$16M

OncoSil phosphorus-32 brachytherapy device for unresectable pancreatic cancer; TGA/CE approved

phase 1$5M

ATR inhibitor PRCH-1 for solid tumours, in-licensed from Merck KGaA